-
Ocera Therapeutics Inc (NASDAQ: OCRX) shares
dropped 68.3 percent to $0.650 after the company reported top-line results for Phase 2b study in Hepatic Encephalopathy.
-
Regulus Therapeutics Inc (NASDAQ: RGLS) shares
declined 50 percent to $1.12 after the company received a written communication from the U.S. Food and Drug Administration that
the clinical development for the company's RG-101 remains on clinical hold.
-
Pulmatrix Inc (NASDAQ: PULM) declined 27.9
percent to $2.43 after surging 51.80 percent on Friday. Pulmatrix reported a $5 million registered direct offering.
-
Tempur Sealy International Inc (NYSE: TPX) shares
dipped 27.6 percent to $45.74 following announcement of termination of Mattress Firm (NASDAQ: MFRM) contracts.
-
Opus Bank (NASDAQ: OPB) fell 23.9 percent to
$20.75. Opus Bank reported a Q4 loss of $0.55 per share.
-
Rite Aid Corporation (NYSE: RAD) dropped 16.4
percent to $5.79. In a merger amendment publicized Monday morning, Walgreens Boots Alliance Inc (NASDAQ: WBA) and Rite Aid agreed to reduce the value of Rite Aid shares
between $6.50 and $7 and to divest a total of 1,200 stores. The initial agreement proposed a divestment of 1,000. The companies
also announced the extension of the transaction deadline to July 31.
-
Rewalk Robotics Ltd (NASDAQ: RWLK) fell 13
percent to $2.00. Rewalk Robotics shares have declined 77.02 percent over the past 52 weeks, while the S&P 500 index has
gained 18.32 percent in the same period.
-
Fitbit Inc (NYSE: FIT) shares tumbled 12.1 percent
to $6.34 after the company surprised investors with a downward revision to its fourth-quarter guidance and a plan to slash
around 6 percent of its total workforce.
-
Costamare Inc (NYSE: CMRE) declined 10.3 percent to
$5.39. Credit Suisse downgraded Costamare from Neutral to Underperform.
-
Globus Maritime Ltd (NASDAQ: GLBS) shares dropped
10 percent to $8.48 after rising 3.51 percent on Friday.
-
Enbridge Energy Partners, L.P. (NYSE: EEP) declined
9.4 percent to $19.33. Mizuho downgraded Enbridge Energy Partners from Buy to Neutral and lowered the price target from $29.00
to $22.00.
-
Booz Allen Hamilton Holding Corporation (NYSE: BAH)
dropped 8.3 percent to $33.25 after the company reported weaker-than-expected earnings for its third quarter.
-
Array Biopharma Inc (NASDAQ: ARRY) declined 7.3
percent to $10.38. Leerink Swann downgraded Array Biopharma from Outperform to Market Perform.
-
FibroGen Inc (NASDAQ: FGEN) fell 6.7 percent to
$21.75. FibroGen disclosed that FG-4592 has met primary endpoints in two Phase 3 anemia studies in China.
-
Rowan Companies PLC (NYSE: RDC) slipped 6.5 percent
to $18.02. Jefferies downgraded Rowan from Buy to Hold.
-
CONSOL Energy Inc. (NYSE: CNX) dropped 6 percent to
$17.86. SunTrust Robinson Humphrey downgraded CONSOL Energy from Buy to Hold.
-
Himax Technologies, Inc. (ADR) (NASDAQ: HIMX)
shares fell 5.2 percent to $5.13. Baird downgraded Himax from Outperform to Neutral.
-
Novan Inc (NASDAQ: NOVN) dropped 4.8 percent to
$4.62 after dipping 74.01 percent on Friday.
-
Paycom Software Inc (NYSE: PAYC) declined 4.6
percent to $46.94. Pacific Crest downgraded Paycom Software from Overweight to Sector Weight.
-
Barclays PLC (ADR) (NYSE: BCS) fell 3 percent to
$11.18. Berenberg downgraded Barclays from Hold to Sell.
Latest Ratings for OCRX
Date |
Firm |
Action |
From |
To |
Dec 2016 |
H.C. Wainwright |
Initiates Coverage On |
|
Buy |
Nov 2016 |
Aegis Capital |
Initiates Coverage On |
|
Buy |
Feb 2016 |
Brean Capital |
Initiates Coverage on |
|
Buy |
View More Analyst Ratings for
OCRX
View the Latest Analyst Ratings
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.